Last updated on December 2018

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6


Brief description of study

The interferon- and ribavirin- (RBV) free combination regimen of glecaprevir plus pibrentasvir (GLE/PIB) for the treatment of genotypes 1 to 6 of chronic hepatitis C (CHC) viral infection has been shown to be safe and effective in randomized controlled clinical trials.

This observational study is an effectiveness research examining the regimen of GLE/PIB, used according to local label, under real world conditions in a clinical practice patient population.

Clinical Study Identifier: NCT03303599

Contact Investigators or Research Sites near you

Start Over

Sadhana Sonparote

Cabinet Medical, Boyer Darrigr /ID# 202050
Nanterre, France
1.58miles
  Connect »

Sadhana Sonparote

Hopital Beaujon /ID# 202675
Clichy, France
6.07miles
  Connect »

Sadhana Sonparote

Hopital Antoine Beclere /ID# 202676
Clamart, France
7.17miles
  Connect »

Sadhana Sonparote

Hopital Bichat-Claude Bernard /ID# 202513
Paris, France
8.02miles
  Connect »

Sadhana Sonparote

Hopital Saint Antoine /ID# 202565
Paris Cedex 12, France
8.34miles
  Connect »

Sadhana Sonparote

Hopital Saint-Louis /ID# 204387
Paris, France
8.34miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.